Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Azeliragon for the Treatment of Pancreatic Cancer

0
22
Cantex Pharmaceuticals, Inc. announced that the US FDA has granted Orphan Drug Designation to Cantex’ azeliragon, a once-a-day pill, for the treatment of pancreatic cancer.
[Cantex Pharmaceuticals, Inc.]
Press Release